Tumor microenvironment promotes breast cancer chemoresistance U Mehraj, AH Dar, NA Wani, MA Mir Cancer chemotherapy and pharmacology, 1-12, 2021 | 175 | 2021 |
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities MAMNAW Umar Mehraj, Rais A. Ganai, Muzafar A. Macha, Abid Hamid, Mohammed A ... cellular Oncology 44 (5), 1-18, 2021 | 82 | 2021 |
Targeting different pathways using novel combination therapy in triple negative breast cancer MA Mir, H Qayoom, U Mehraj, S Nisar, B Bhat, NA Wani Current cancer drug targets 20 (8), 586-602, 2020 | 77 | 2020 |
Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors S Sofi, U Mehraj, H Qayoom, S Aisha, A Almilaibary, M Alkhanani, MA Mir Medical Oncology 39 (9), 133, 2022 | 74 | 2022 |
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer H Qayoom, NA Wani, B Alshehri, MA Mir Future oncology 17 (31), 4185-4206, 2021 | 74 | 2021 |
Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications S Sofi, U Mehraj, H Qayoom, S Aisha, SMB Asdaq, A Almilaibary, MA Mir Medical oncology 39 (6), 106, 2022 | 64 | 2022 |
Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives U Mehraj, H Qayoom, MA Mir Breast Cancer 28 (3), 539-555, 2021 | 63 | 2021 |
Nanobodies: The “magic bullets” in therapeutics, drug delivery and diagnostics MA Mir, U Mehraj, BA Sheikh, SS Hamdani Human antibodies 28 (1), 29-51, 2020 | 57 | 2020 |
Introduction to costimulation and costimulatory molecules. Developing Costimulatory Molecules for Immunotherapy of Diseases M Mir Academic Press, 2015 | 56 | 2015 |
Introduction to Costimulation and Costimulatory Molecules. MA Mir Developing Costimulatory Molecules for Immunotherapy of Diseases 3, 147-198, 2015 | 53 | 2015 |
Double-crosser of the immune system: macrophages in tumor progression and metastasis MA Mir, U Mehraj Current immunology reviews 15 (2), 172-184, 2019 | 45 | 2019 |
Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications U Mehraj, U Mushtaq, MA Mir, A Saleem, MA Macha, MN Lone, A Hamid, ... Seminars in Cancer Biology 86, 769-783, 2022 | 44 | 2022 |
Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: a comprehensive analysis U Mehraj, S Aisha, S Sofi, MA Mir Advances in Cancer Biology-Metastasis 4, 100037, 2022 | 43 | 2022 |
Development of new therapeutics to meet the current challenge of drug resistant tuberculosis BA Sheikh, BA Bhat, U Mehraj, W Mir, S Hamadani, MA Mir Current pharmaceutical biotechnology 22 (4), 480-500, 2021 | 41 | 2021 |
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes Manzoor MA, Haseeb A, Qadri H Current Drug Targets 22 (12), 1424-1436, 2021 | 39 | 2021 |
Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi H Qadri, AH Shah, SM Ahmad, B Alshehri, A Almilaibary, MA Mir Saudi Journal of Biological Sciences 29 (9), 103376, 2022 | 35 | 2022 |
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis H Qayoom, S Sofi, MA Mir Immunologic research 71 (4), 588-599, 2023 | 33 | 2023 |
Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study H Qayoom, U Mehraj, S Sofi, S Aisha, A Almilaibary, M Alkhanani, MA Mir Medical oncology 39 (10), 158, 2022 | 32 | 2022 |
Signaling through CD80: an approach for treating lymphomas MA Mir, JN Agrewala Expert opinion on therapeutic targets 12 (8), 969-979, 2008 | 31 | 2008 |
Expression pattern and prognostic significance of chemokines in breast cancer: an integrated bioinformatics analysis U Mehraj, B Alshehri, AA Khan, AA Bhat, P Bagga, NA Wani, MA Mir Clinical Breast Cancer 22 (6), 567-578, 2022 | 29 | 2022 |